Clinical Trial Update: Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting long-term safety of SPD422 in Japanese adults with essential thrombocythemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• SPD422

Snippet

Sponsor: Shire | Conditions: Essential Thrombocythemia (ET) | Phase 3 | Status: COMPLETED | Results posted: 2016-06-08